Baseline characteristics of patients with transthyretin amyloidosis with cardiomyopathy in the CARDIO-TTRansform trial of eplontersen - PubMed
4 hours ago
- #Eplontersen
- #ATTR-CM
- #Cardiomyopathy Trial
- CARDIO-TTRansform trial evaluates eplontersen in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM).
- Baseline data included 1432 patients (mean age 76.4 years, 9.4% female, 88.8% White) with varied disease severity and functional classes.
- Hereditary/variant ATTR-CM (ATTRv-CM) present in 14.7%, with Val122Ile as the most common genotype.
- Key biomarkers: median NT-proBNP 2025 pg/ml, median hs-troponin T 50 pg/ml, and mean LVEF 55.7%.
- At baseline, 57.2% were on TTR stabilizers and 18.4% on SGLT2 inhibitors, reflecting contemporary standard care.
- Findings align with previous ATTR-CM trials but encompass a broader disease severity range.